ARS Pharmaceuticals files US antitrust claims against AptarGroup over emergency nasal sprays
MLex Summary: ARS Pharmaceuticals Operations filed a US complaint accusing AptarGroup of illegally limiting competition to its emergency-use single-dose intranasal spray system through exclusionary policies to delay competitive entry and thereby...To view the full article, register now.
Already a subscriber? Click here to view full article